Showing 1 - 10 of 11
Persistent link: https://www.econbiz.de/10011975970
-produced penicillin, antimalarials, and a flu vaccine. We draw on this episode to discuss the economics of crisis innovation. Since the …
Persistent link: https://www.econbiz.de/10012482553
Innovation policy can be a crucial component of governments' responses to crises. Because speed is a paramount … objective, crisis innovation may also require different policy tools than innovation policy in non-crisis times, raising … distinct questions and tradeoffs. In this paper, we survey the U.S. policy response to two crises where innovation was crucial …
Persistent link: https://www.econbiz.de/10012585399
This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....
Persistent link: https://www.econbiz.de/10013462677
impact on the U.S. innovation system, catalyzing technology clusters around the country with accompanying increases in high …. In the aggregate, wartime R&D permanently changed the trajectory of U.S. innovation in the direction of funded …
Persistent link: https://www.econbiz.de/10014031891
"Are scientific knowledge flows embodied in individuals, or "in the air"? To answer this question, we measure the effect of labor mobility in a sample of 9,483 elite academic life scientists on the citation trajectories associated with individual articles (resp. patents) published (resp....
Persistent link: https://www.econbiz.de/10008822959
Persistent link: https://www.econbiz.de/10009550110
Persistent link: https://www.econbiz.de/10012254600
Persistent link: https://www.econbiz.de/10011416999
In December 2023, the Biden-Harris Administration released a proposed framework for exercising government "march-in" rights on high-priced taxpayer-funded drugs. While both proponents and critics of the new rules view them as having broad scope, march-in rights can be exercised only on patents...
Persistent link: https://www.econbiz.de/10014512071